Nuvectis PharmaNVCT
NVCT
About: Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Employees: 13
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
8% more capital invested
Capital invested by funds: $6.6M [Q3] → $7.15M (+$546K) [Q4]
1.21% more ownership
Funds ownership: 5.63% [Q3] → 6.84% (+1.21%) [Q4]
0% more funds holding
Funds holding: 31 [Q3] → 31 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
51%
upside
Avg. target
$17
71%
upside
High target
$19
91%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target | 51%upside $15 | Buy Reiterated | 30 Apr 2025 |
Maxim Group Naz Rahman 8% 1-year accuracy 1 / 12 met price target | 71%upside $17 | Buy Initiated | 2 Apr 2025 |
Laidlaw & Co. Yale Jen 33% 1-year accuracy 2 / 6 met price target | 91%upside $19 | Buy Initiated | 17 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 day ago
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC Fort Lee, NJ, April 29, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology today provided poster presentation highlights for NXP900 from the 2025 American Association for Cancer Research Meeting (2025 AACR). These posters highlight key data supporting the rationale for the Phase 1b program in biomarker-selected cancers as a single agent, and in combination with market leading therapies to overcome treatment resistance in non-small cell lung cancer (NSCLC).
Neutral
GlobeNewsWire
1 month ago
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California.
Neutral
Business Wire
1 month ago
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
NEW YORK--(BUSINESS WIRE)---- $NVCT #Cancerstocks--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to dec.
Neutral
Business Wire
2 months ago
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
NEW YORK--(BUSINESS WIRE)---- $NVCT #Pharma--Market News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma (Nasdaq: NVCT) with a Buy rating and a price target of $18. The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need. Lucid's report emphasizes the strong potential of NXP900, which is currently in Phase 1 clinical trials and has shown an encouraging safe.
Neutral
GlobeNewsWire
2 months ago
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter's option to purchase 405,000 additional shares. The common stock shares were offered at a price of $5.00 per share, resulting in gross proceeds to Nuvectis of approximately $15.5 million, before deducting underwriting discounts and commissions.
Positive
Seeking Alpha
2 months ago
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback
The company's stock dropped due to disappointing phase 1b results for NXP800 in ARID1a-mutated ovarian cancer, but higher dosing may improve outcomes in Q2 2025. The company is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting toxicities. The global ovarian cancer market is expected to reach $11.18 billion by 2029.
Neutral
GlobeNewsWire
2 months ago
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price of $5.00 per share, with expected gross proceeds to Nuvectis of $13.5 million. Nuvectis has also granted the underwriter a 30-day option to purchase up to 405,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 6, 2025, subject to customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
FORT LEE, NJ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In addition, Nuvectis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
Zacks Investment Research
5 months ago
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Nuvectis Pharma (NVCT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Negative
Benzinga
5 months ago
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma, Inc. NVCT stock is trading lower after the company reported data from the Phase 1b study evaluating NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer.
Charts implemented using Lightweight Charts™